Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Daniel Eshtiaghpour

Gastroenterology Los Angeles, CA Medical Doctor

NPI 1962780148 CMS profile 5026621

200 Med Plaza Suite 365, 420, 120, Los Angeles, CA 90095

Open in the dashboard

General payments

$4,712

233 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Daniel Eshtiaghpour of Los Angeles, CA is reported in the CMS Open Payments database as having received $4,712 across 233 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 65th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $304 16
2024 General $1,539 76
2023 General $1,230 62
2022 General $811 42
2021 General $814 36
2019 General $14 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Eshtiaghpour
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Daniel Eshtiaghpour were reported at $304. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Daniel Eshtiaghpour Gastroenterology median Middle half National median
2019 $14 $417 $126–$1,100 $163
2020 $0 $224 $74–$624 $114
2021 $814 $352 $106–$1,054 $132
2022 $811 $448 $129–$1,270 $149
2023 $1,230 $533 $150–$1,390 $160
2024 $1,539 $605 $160–$1,606 $164
2025 $304 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,398 131 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $806 38 payments
  3. Genzyme Corporation $419 18 payments
  4. Ardelyx, Inc. $288 12 payments
  5. QOL Medical, LLC $186 9 payments
  6. Janssen Biotech, Inc. $131 6 payments
  7. Ferring Pharmaceuticals Inc. $109 6 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $84 4 payments
  9. Apollo Endosurgery US Inc $77 1 payment
  10. Endogastric Solutions, Inc $77 1 payment
  11. Other $139 7 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,680 232 payments
  2. Education $32 1 payment
Products named General payments · program years 2019–2025
  1. RINVOQ $1,352 74 payments
  2. SKYRIZI Immunology $1,053 64 payments
  3. XIFAXAN $770 31 payments
  4. DUPIXENT $419 18 payments
  5. HUMIRA $367 21 payments
  6. TRULANCE $305 9 payments
  7. IBSRELA $288 12 payments
  8. SKYRIZI Immunology $140 8 payments
  9. Sucraid $122 6 payments
  10. TREMFYA $96 4 payments
  11. Other $886 42 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 29 drugs

Part D claims

1,886

Median for Gastroenterology: 569

Drug cost

$358,723

Median for Gastroenterology: $104,976

Branded share of claims

29.9%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Linzess Linaclotide Brand 108 $72,408
Creon Lipase/Protease/Amylase Brand 39 $66,162
Chlordiazepoxide-Clidinium Chlordiazepoxide/Clidinium Br Brand 18 $42,261
Zenpep Lipase/Protease/Amylase Brand 19 $38,416
Alosetron Hcl Generic 21 $25,940
Ibsrela Tenapanor Hcl Brand 13 $22,669
Motegrity Prucalopride Succinate Brand 20 $14,979
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 179 $10,420
Mesalamine Generic 24 $10,009
Pantoprazole Sodium Generic 514 $8,244

The 10 drugs with the highest cost, of 29 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 28 billing codes

Paid by Medicare

$99,108

Medicare's payments for the services billed

Medicare patients

416

Average age 73

Services billed

1,009

252 women, 164 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 62%
Ischemic heart disease 39%
Depression 39%
Diabetes 31%
Cancer 25%
Osteoporosis 25%
Chronic kidney disease 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SKYRIZI
  • AbbVie, Inc. $477
$477 — —
RINVOQ
  • AbbVie, Inc. $436
$436 — —
DUPIXENT
  • GENZYME CORPORATION $160
$160 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $116
$116 — —
TREMFYA
  • Janssen Biotech, Inc. $96
$96 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

233 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record